Kamada Ltd. (NASDAQ:KMDA) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a 12-month consensus target price of $8.50 for the company and are predicting that the company will post $0.04 EPS for the current quarter, according to Zacks. Zacks has also assigned Kamada an industry rank of 111 out of 265 based on the ratings given to its competitors.
Several brokerages have weighed in on KMDA. Zacks Investment Research lowered shares of Kamada from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 16th. Jefferies Group LLC restated a “buy” rating and set a $7.00 target price on shares of Kamada in a research report on Thursday, October 12th. ValuEngine lowered shares of Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, TheStreet lowered shares of Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st.
WARNING: “Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages” was first posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/11/21/kamada-ltd-kmda-given-8-50-average-target-price-by-brokerages.html.
Shares of Kamada (KMDA) traded up $0.05 during trading on Tuesday, hitting $4.70. 34,328 shares of the stock were exchanged, compared to its average volume of 71,949. Kamada has a twelve month low of $3.75 and a twelve month high of $8.61. The company has a current ratio of 3.71, a quick ratio of 2.73 and a debt-to-equity ratio of 0.02.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.